Exhibit 6.2NON-EXCLUSIVE LICENSE AGREEMENTBETWEENTHE JOHNS HOPKINS UNIVERSITYVIRTUOSO SURGICAL, INC.JHU Agreement: A29889Source: VIRTUOSO SURGICAL, INC., 1-A, 12/27/20191May 3, 2016NON-EXCLUSIVE LICENSE AGREEMENT- FOR SALESThis Non-Exclusive License Agreement (hereinafter “Agreement”) is entered into by and between The Johns Hopkins University(hereinafter “JHU”), a corporation of the State of Maryland, having a principal place of business 3400 N. Charles Street, Baltimore, Maryland 21218-2695 and, Virtuoso Surgical, Inc. (hereinafter “Company”), a Tennessee corporation having an address at 5701 Old Harding Pike; Suite 200;Nashville, TN 37205. The parties hereto agree as follows:1. BACKGROUND1.1In the course of a fundamental research program at JHU, a valuable invention entitled Active Cannulas for Bio-Sensing andSurgical Intervention (JHU Ref. C04873) was developed by Drs. Robert Webster, III, Noah Cowan, Allison Okamura, and RussellTaylor (hereinafter “Inventors”).1.2JHU has acquired all right, title and interest, with the exception of certain retained rights by the United States government, in saidinvention but is without the capacity to commercially develop, manufacture and distribute products and methods which embodythe invention.1.3Company is interested in providing such commercial products and methods to third parties on a non-exclusive basis and agreesto comply with the terms and conditions in this Agreement.1.4All references to particular Exhibits or Paragraphs shall mean the Exhibits to, and Paragraphs of, this Agreement, unless otherwisespecified.2. DEFINITIONS2.1“EFFECTIVE DATE” of this Agreement shall mean the date the last party hereto has executed this Agreement.2.2“LICENSED FIELD” shall mean Cannulated Surgical Intervention.2.3“LICENSED PRODUCT(S)” as used herein in either singular or plural shall mean any material, compositions, or other product, themanufacture, use or sale of which would constitute, but for the license granted to Company pursuant to this Agreement, aninfringement of a claim of PATENT RIGHT(S) (infringement shall include, but is not limited to, direct, contributory, or inducementto infringe).2.4“LICENSED SERVICE(S)” as used herein in either singular or plural shall mean the performance on behalf of a third party of anymethod including cannulated surgical intervention or the manufacture of any product or the use of any product which wouldconstitute, but for the license granted to Company pursuant to this Agreement, an infringement of a claim of the PATENTRIGHT(S), (infringement shall include, but not be limited to, direct, contributory or inducement to infringe).Source: VIRTUOSO SURGICAL, INC., 1-A, 12/27/20192May 3, 20162.5“NET SALES” shall mean gross sales revenues and fees billed by Company from the sale of LICENSED PRODUCT(S) less tradediscounts allowed, refunds, returns and recalls, and sales taxes. In the event that Company sells a LICENSED PRODUCT(S) incombination with other ingredients or substances or as part of a kit, the NET SALES for purposes of royalty payments shall bebased on the sales revenues and fees received from the entire combination or kit.2.6“NET SERVICE REVENUES” shall mean gross service revenues and fees billed by Company for the performance of LICENSEDSERVICE(S) less sales and/or use taxes imposed upon and with specific reference to the LICENSED SERVICE(S). In the event thatCompany sells a LICENSED SERVICE(S) in combination with other services or substances or as part of a kit, the NET SERVICEREVENUES for purposes of royalty payments shall be based on the sales revenues and fees received from the entirecombination.2.7“PATENT RIGHT(S)” shall mean, collectively, JHU’s interest in those set forth in EXHIBIT C of this Agreement and theinventions disclosed and claimed therein, and all continuations, divisions, and reissues based thereof, and any correspondingforeign patent applications, and any patents, or other equivalent foreign PATENT RIGHT(S) issuing, granted or registeredthereon.3. GRANT3.1License Granted: Subject to the terms and conditions of this Agreement and to non-exclusive license agreements executed priorto the EFFECTIVE DATE, JHU hereby grants to the Company a non-exclusive, non-transferable license to make, have made,import, offer for sale and sell the LICENSED PRODUCT(S) and the LICENSED SERVICE(S) in the United States and worldwideunder the PATENT RIGHT(S) in the LICENSED FIELD.3.2No Sublicensing: Company shall not sublicense to others under this Agreement, nor extend the rights granted hereunder to anyaffiliated company.4. PAYMENTS, ROYALTY AND REPORTING4.1License Fee: As consideration for JHU’s grant of a License to Company under this Agreement, Company shall pay to JHU alicense fee, cash and equity, as set forth in Exhibit A within thirty (30) days of the EFFECTIVE DATE. The license fee isnonrefundable and shall not be credited against royalties or other fees.4.2Minimum Annual Royalties: Company shall pay to JHU minimum annual royalties as set forth in Exhibit A. These minimum annualroyalties shall be due within thirty (30) days of each anniversary of the EFFECTIVE DATE beginning with the first anniversary.Running royalties accrued under Paragraph 4.3 and paid to JHU during the one year period preceding an anniversary of theEFFECTIVE DATE shall be credited against the minimum annual royalties due on that anniversary date.Source: VIRTUOSO SURGICAL, INC., 1-A, 12/27/20193May 3, 20164.3Running Royalties: Company shall pay to JHU, a running royalty as set forth in Exhibit A, for each LICENSED PRODUCT(S) soldand each LICENSED SERVICE(S) provided, based upon NET SALES and NET SERVICE REVENUES respectively, for the term ofthis Agreement. Such payments shall be made within thirty (30) days of the end of each calendar quarter following firstcommercial sale of LICENSED PRODUCT or providing LICENSED SERVICES. All non-US taxes related to LICENSEDPRODUCT(S) and LICENSED SERVICE(S) sold under this Agreement shall be paid by Company and shall not be deducted fromroyalty or other payments due to JHU.4.4Reporting and Payments: Upon achieving first commercial sale of LICENSED PRODUCTS and LICENSED SERVICES, Companyshall provide a quarterly royalty report, substantially in the format of Exhibit B, accompanying each royalty payment as requiredin Paragraph 4.3. Royalty reports shall disclose the amount of LICENSED PRODUCT(S) and LICENSED SERVICE(S) sold, thetotal NET SALES and NET SERVICE REVENUES of such LICENSED PRODUCT(S) and LICENSED SERVICE(S), and the runningroyalties due to JHU as a result of NET SALES and NET SERVICE REVENUES by Company. In lieu of sending quarterly royaltyreports to JHU via mail or courier, Company may provide all required reports in electronic format to the email address specified byJHU.4.5Late Payments: In the event that any payment due hereunder is not made when due, the payment shall accrue interest beginningon the tenth day following the due date thereof, calculated at the annual rate of six percent (6%), the interest being compoundedon the last day of each calendar year. Each such royalty payment when made shall be accompanied by all interest so accrued.Said interest and the payment and acceptance thereof shall not negate or waive the right of JHU to seek any other remedy, legalor equitable, to which it may be entitled because of the delinquency of any payment.4.6Records: The Company shall make and retain, for a period of three (3) years following the period of each report required byParagraph 4.4, true and accurate records, files and books of account containing all the data reasonably required for the fullcomputation and verification of sales and other information required in Paragraph 4.4. Such books and records shall be inaccordance with generally accepted accounting principles consistently applied. The Company shall permit the inspection andcopying of such records, files and books of account by JHU or its agents during regular business hours upon ten (10) businessdays’ written notice to the Company. Such inspection shall not be made more than once each calendar year. All costs of suchinspection and copying shall be paid by JHU, provided that if any such inspection shall reveal that an error has been made in theamount equal to five percent (5%) or more of such payment, such costs shall be borne by the Company.Source: VIRTUOSO SURGICAL, INC., 1-A, 12/27/20194May 3, 20164.7Non-Arms Length Transactions: In order to insure JHU the full royalty payments contemplated hereunder, the Company agreesthat in the event any LICENSED PRODUCT(S) shall be sold to an affiliated company or to a corporation, firm or association withwhich Company shall have any agreement, understanding or arrangement with respect to consideration (such as, among otherthings, an option to purchase stock or actual stock ownership, or an arrangement involving division of profits or special rebatesor allowances) the royalties to be paid hereunder for such LICENSED PRODUCT(S) shall be based upon the greater of: 1) the netselling price at which the purchaser of LICENSED PRODUCT(S) resells such product to the end user, 2) the NET SERVICEREVENUE received from using the LICENSED PRODUCT(S) in providing a service, 3) the fair market value of the LICENSEDPRODUCT(S) or 4) the net selling price of LICENSED PRODUCT(S) paid by the purchaser.4.8Method of Payment: All payments under this Agreement shall be made in U.S. Dollars by either check or wire transfer.4.9Payment Information. All check payments from Company to JHU shall be sent to:DirectorJohns Hopkins Technology VenturesThe Johns Hopkins University100 N. Charles Street, 5th FloorBaltimore, MD 21201Reference: JHU Agreement A29889or such other addresses which JHU may designate in writing from time to time. Checks are to be made payable to “The JohnsHopkins University”.Wire transfers may be made through:ACH for U.S. PaymentsJohns Hopkins University Central LockboxBank of America1400 Best Plaza DriveRichmond, VA 23227Transit/routing/ABA number: 052001633Account number:Type of account: depositoryCTX format is preferred; CCD is also acceptedReference: JHU Tech Transfer (JHU Agreement A29889)FED WIRE for International PaymentsJohns Hopkins University Central LockboxBank of America100 West 33rd Street New York, NY 10001SWIFT code: BOFAUS3NAccount number:Type of account: depositorySource: VIRTUOSO SURGICAL, INC., 1-A, 12/27/20195May 3, 2016Reference: JHU Tech Transfer (JHU Agreement A29889)Company shall be responsible for any and all costs associated with wire transfers. Company shall provide JHU with the date ofwire transfer payment and ACH confirmation number upon completion of such payment.4.10Invoices. Any invoice for payment sent by JHU to Company may be electronically provided by e-mail service. JHU will sendinvoices to an e-mail address provided by Company. Company will provide JHU with any updates to this e-mail address.5. PATENT MATTERS5.1Prosecution Maintenance: JHU, at its sole option and discretion, shall file, prosecute and maintain all patents and patentapplications specified under PATENT RIGHT(S). Title to all such patents and patent applications shall reside in JHU. JHU shallhave full and complete control over all patent matters in connection therewith under the PATENT RIGHT(S).5.2Right to Enforce: JHU shall have the first right to enforce the PATENT RIGHTS against any infringement or alleged infringementthereof in the LICENSED FIELD OF USE.6. TERM AND TERMINATION6.1Expiration: This term of this Agreement shall commence on the EFFECTIVE DATE and shall continue, in each country, until thedate of expiration of the last to expire patent within PATENT RIGHT(S) in that country.6.2Termination by Company: Company may terminate this Agreement and the license granted herein, for any reason, upon givingJHU sixty (60) days written notice under Paragraph 8.1.6.3Termination by JHU: JHU, at its option, may terminate this Agreement and the license granted herein if Company has not madeany sales of LICENSED PRODUCT(S) or LICENSED SERVICE(S) in any period of four consecutive quarters, after the initialcommercial sale of the PRODUCT(S) or LICENSED SERVICE(S).6.4Unpaid Royalty/Reversion of Rights: Termination or expiration of this Agreement shall not affect JHU’s right to recover unpaidroyalties accrued prior to termination or expiration. Upon termination or expiration of this Agreement, all rights in and to thelicensed technology shall revert to JHU at no cost to JHU.6.5Survival: All applicable provisions, including but not limited to Paragraphs 4.1 (License Fee), 9.3 (Severability), 9.4 (Use of Name),9.6 (Disclaimer of Warranties), 9.7 (Indemnification), 9.8 (Product Liability), 9.13 (Binding Effect) and 9.14 (Governing Law) shallsurvive termination or expiration of this Agreement.Source: VIRTUOSO SURGICAL, INC., 1-A, 12/27/20196May 3, 20167. DEFAULT7.1Default Termination: Upon breach or default of any term or condition of this Agreement by either party, the defaulting partyshall be given written notice of such default in writing by the party not in default. The defaulting party shall have a period of sixty(60) days after receipt of such notice to correct the default or breach. If the default or breach is not corrected within said sixty (60)day period, the party not in default shall have the right to terminate this Agreement.8. NOTICES8.1Notice Information: All notices and/or other communications pertaining to this Agreement shall be in writing and sent byregistered mail or certified mail, return receipt requested, or sent by overnight courier, such as Federal Express, to the parties atthe following addresses or such other address as such party shall have furnished in writing to the other party in accordance withthis Paragraph 8.1:FOR JHU:DirectorJohns Hopkins Technology VenturesThe Johns Hopkins University100 N. Charles Street, 5th FloorBaltimore, MD 21201Reference: JHU Agreement A29889FOR Company:VIRTUOSO SURGICAL, INC.5701 Old Harding Pike; Suite 200Nashville, TN 372059. MISCELLANEOUS9.1Audit: JHU shall have the right to audit any and all Company records related to this Agreement.9.2Assignment: This Agreement is binding upon and shall inure to the benefit of JHU, its successors and assignees and shall not beassignable to another party, except that the Company shall have the right to assign this Agreement to another party in the case ofthe sale or transfer by the Company of all, or substantially all, of its assets relating to the LICENSED PRODUCT(S), LICENSEDSERVICE(S) or PATENT RIGHT(S), to that party.Source: VIRTUOSO SURGICAL, INC., 1-A, 12/27/20197May 3, 20169.3Severability: In the event that any one or more of the provisions of this Agreement should for any reason be held by any court orauthority having jurisdiction over this Agreement, or over any of the parties hereto to be invalid, illegal or unenforceable, suchprovision or provisions shall be reformed to approximate as nearly as possible the intent of the parties, and if unreformable, shallbe divisible and deleted in such jurisdictions; elsewhere, this Agreement shall not be affected.9.4Use of Name: The Company shall not use the name of The Johns Hopkins University or The Johns Hopkins Health System orany of its constituent parts, such as the Johns Hopkins Hospital or any contraction thereof or the name of Inventors in anyadvertising, promotional, sales literature or fundraising documents without prior written consent from an authorizedrepresentative of JHU. Company shall allow at least seven (7) business days notice of any proposed public disclosure for JHU’sreview and comment or to provide written consent.9.5Duties of the Parties: JHU is not a commercial organization. It is an institute of research and education. Therefore, JHU has noability to evaluate the commercial potential of any PATENT RIGHT(S), LICENSED PRODUCT(S), LICENSED SERVICE(S) or otherlicense or rights granted in this Agreement. It is therefore incumbent upon Company to evaluate the rights and products inquestion, to examine the materials and information provided by JHU, and to determine for itself the validity of any PATENTRIGHT(S), its freedom to operate, and the value of any LICENSED PRODUCT(S) or LICENSED SERVICE(S) or other rightsgranted.9.6Disclaimer of Warranties: JHU does not warrant the validity of any patents or that the practice under such patents, or themanufacture, use, sale or import of LICENSED PRODUCT(S) or LICENSED SERVICE(S), shall be free from patent infringement.EXCEPT AS EXPRESSLY SET FORTH IN THIS PARAGRAPH 9.6, COMPANY AGREES THAT THE PATENT RIGHT(S) AREPROVIDED “AS IS”, AND THAT JHU MAKES NO REPRESENTATION OR WARRANTY WITH RESPECT TO THEPERFORMANCE OF LICENSED PRODUCTS OR LICENSED SERVICES INCLUDING THEIR SAFETY, EFFECTIVENESS, ORCOMMERCIAL VIABILITY. JHU DISCLAIMS ALL WARRANTIES WITH REGARD TO LICENSED PRODUCTS AND LICENSEDSERVICES UNDER THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ALL WARRANTIES, EXPRESS OR IMPLIED, OFMERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE. NOTWITHSTANDING ANY OTHER PROVISION OFTHIS AGREEMENT, JHU ADDITIONALLY DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF JHU ANDINVENTORS, FOR DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT, SPECIAL, AND CONSEQUENTIALDAMAGES, ATTORNEYS’ AND EXPERTS’ FEES, AND COURT COSTS (EVEN IF JHU HAS BEEN ADVISED OF THEPOSSIBILITY OF SUCH DAMAGES, FEES OR COSTS), ARISING OUT OF OR IN CONNECTION WITH THE MANUFACTURE,USE, OR SALE OF THE LICENSED PRODUCTS AND LICENSED SERVICES UNDER THIS AGREEMENT. COMPANY ASSUMESALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED BY ANY PRODUCT OR SERVICEMANUFACTURED, USED, OR SOLD BY COMPANY WHICH IS A LICENSED PRODUCT OR LICENSED SERVICE AS DEFINEDIN THIS AGREEMENT.Source: VIRTUOSO SURGICAL, INC., 1-A, 12/27/20198May 3, 20169.7Indemnification: JHU and the Inventors will have no legal liability exposure to third parties if JHU does not license the LICENSEDPRODUCT(S) and LICENSED SERVICE(S), and any royalties JHU and the Inventors may receive is not adequate compensationfor such legal liability exposure. Therefore, JHU requires Company to protect JHU and Inventors from such exposure to the samemanner and extent to which insurance, if available, would protect JHU and Inventors. JHU and the Inventors will not, under theprovisions of this Agreement or otherwise, have control over the manner in which Company or those operating for its account orthird parties who purchase LICENSED PRODUCT(S) or LICENSED SERVICE(S) from any of the foregoing entities, practice theinventions of LICENSED PRODUCT(S) and LICENSED SERVICE(S). The Company shall indemnify, defend with counselreasonably acceptable to JHU, and hold JHU, The Johns Hopkins Health Systems, their representatives including but not limitedto present and former, trustees, officers, Inventors, agents, faculty, employees and students harmless as against any judgments,fees, expenses, or other costs arising from or incidental to any product liability or other lawsuit, claim, demand or other actionbrought as a consequence of the practice of said inventions by any of the foregoing entities, whether or not JHU or saidInventors, either jointly or severally, is/are named as a party defendant in any such lawsuit. Practice of the inventions covered byLICENSED PRODUCT(S) or LICENSED SERVICE(S) by an agent or a third party on behalf of or for the account of the Company,or by a third party who purchases LICENSED PRODUCT(S) or LICENSED SERVICE(S) from the Company, shall be considered theCompany’s practice of said inventions for purposes of this Paragraph 9.7. The obligation of the Company to defend andindemnify as set out in this Paragraph 9.7 shall survive the termination of this Agreement and shall not be limited by any otherlimitation of liability elsewhere in the Agreement.9.8Product Liability: Prior to first commercial sale of any LICENSED PRODUCT(S) or LICENSED SERVICE(S) as the case may be inany particular country, Company shall establish and maintain, in each country in which Company shall sell LICENSEDPRODUCT(S) or LICENSED SERVICE(S), product liability or other appropriate insurance coverage appropriate to the risksinvolved in marketing LICENSED PRODUCT(S) and/or LICENSED SERVICE(S) and will annually present evidence to JHU thatsuch coverage is being maintained. Upon JHU’s request, Company will furnish JHU with a Certificate of Insurance of eachproduct liability insurance policy obtained. JHU shall be listed as an additional insured in Company’s said insurance policies. Ifsuch Product Liability insurance is underwritten on a ‘claims made’ basis, Company agrees that any change in underwritersduring the term of this Agreement will require the purchase of ‘prior acts’ coverage to ensure that coverage will be continuousthroughout the term of this Agreement.9.9Entire Agreement: This Agreement constitutes the entire understanding between the parties with respect to the obligations of theparties with respect to the subject matter hereof, and supersedes and replaces all prior agreements, understandings, writings, anddiscussions between the parties relating to said subject matter.Source: VIRTUOSO SURGICAL, INC., 1-A, 12/27/20199May 3, 20169.10Amendment Waiver: This Agreement may be amended and any of its terms or conditions may be waived only by a writteninstrument executed by the authorized officials of the parties or, in the case of a waiver, by the party waiving compliance. Thefailure of either party at any time or times to require performance of any provision hereof shall in no manner affect its right at alater time to enforce the same. No waiver by either party of any condition or term in any one or more instances shall be construedas a further or continuing waiver of such condition or term or of any other condition or term.9.11Binding Effect: This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto andtheir respective successors and permitted assigns.9.12Governing Law: This Agreement shall be construed, and legal relations between the parties hereto shall be determined, inaccordance with the laws of the State of Maryland applicable to contracts solely executed and wholly to be performed within theState of Maryland without giving effect to the principles of conflicts of laws. Any disputes between the parties to the Agreementshall be brought in the state or federal courts of Maryland. Both parties agree to waive their right to a jury trial.9.13Headings: Article headings are for convenient reference and are not a part of this Agreement. All Exhibits are incorporated hereinby this reference.9.14Use of Name: Nothing contained in this Agreement confers any right to either party hereto to use in advertising, publicity, orother promotional activities any name, trade name, trademark, or other designation of the other party hereto (including anycontraction, abbreviation or simulation of any of the foregoing).Unless otherwise required by law, LICENSEE is prohibited from using the name “The Johns Hopkins University” or the name ofany affiliate of the Johns Hopkins University, including but not limited to The Johns Hopkins Health System Corporation, or anyof its hospitals or affiliates, or the names of any of their respective faculty, employees, students or INVENTORS, in advertising,publicity, or other promotional activities, without JHU’s prior written approval of such use.JHU may disclose to all INVENTORS the terms and conditions of this Agreement upon their request.JHU may acknowledge to third parties the existence of this Agreement and the extent of the licenses granted to LICENSEE andAFFILIATES under Section 3 hereof, but JHU shall not disclose the financial terms of this Agreement to third parties, exceptwhere JHU is required by law to do so. LICENSEE hereby grants JHU permission to include LICENSEE’s name and a link toLICENSEE’s website in JHU’s annual reports and on JHU’s website to showcase technology transfer-related stories.JHU shall have the right to list LICENSEE and display the logotype or symbol of LICENSEE on JHU’s website and on JHUpublications as a licensee startup company based upon JHU technology.Source: VIRTUOSO SURGICAL, INC., 1-A, 12/27/201910May 3, 2016IN WITNESS WHEREOF the respective parties hereto have executed this Agreement by their duly authorized officers on the date appearing belowtheir signatures.THE JOHNS HOPKINS UNIVERSITYVIRTUOSO SURGICAL, INC.By: /s/ Neil VelosoBy:/s/ C. Mark PickrellNeil VelosoName:C. Mark PickrellExecutive DirectorTitle: Attorney-in-FactJohns Hopkins Technology VenturesDate:5/11/2016Date:: 5/4/2016Source: VIRTUOSO SURGICAL, INC., 1-A, 12/27/201911May 3, 2016EXHIBIT ALICENSE FEES and ROYALTY1. LICENSE FEE1.1The license fee due under Paragraph 4.1 is two-thousand dollars (2000).1.2In addition, COMPANY shall issue to JHU that number of shares of common stock representing five percent (5%) of theoutstanding common and preferred shares on a fully diluted basis of COMPANY pursuant to an agreed upon stock purchaseagreement between COMPANY and JHU. The stock purchase agreement shall contain provisions protecting JHU against dilutionof its equity interest in the event the post-money valuation of any equity investment is less than two million dollars (2,000,000),and it will also contain a provision for the piggy-back registration of common shares with any other class of stock in an initialpublic offering. If COMPANY proposes to sell any equity securities or securities that are convertible into equity securities ofCOMPANY (collectively, “Equity Securities”) in any new round of financing, then COMPANY shall offer JHU and/or its Assignee(as defined below) an opportunity to purchase either:(i)up to that portion of the Equity Securities that equals JHU’s then current, fully-diluted percentage ownership interest inCOMPANY, or(ii)if the percentage offered for sale by COMPANY is less, then up to five percent (5%) of the Equity Securities offered forsale. Such offer to purchase shall be on the same terms and conditions as are offered with respect to such EquitySecurities sold in such financing. For purposes of this section 7 of Exhibit A, the term “Assignee” means: (a) any entityto which JHU’s preemptive rights have been assigned either by JHU or by another entity, or (b) any entity that iscontrolled by JHU.2. EARNED ROYALTY2.1Annual Earned Royalty. COMPANY shall pay an annual EARNED ROYALTY as follows:2.1.1 Four percent (4%) of the sum of NET REVENUES.2.2Royalty Stacking. If COMPANY is required to pay running royalties on any patent rights not licensed hereunder (“OtherRoyalties”) in order to make, use or sell a particular LICENSED PRODUCT or LICENSED SERVICE, COMPANY shall be entitled tocredit half (50%) of such Other Royalties against the Earned Royalty due, but the Earned Royalties shall not be reduced belowfifty percent (50%) of those that would otherwise be due JHU for that LICENSED PRODUCT or LICENSED SERVICE.Source: VIRTUOSO SURGICAL, INC., 1-A, 12/27/201912May 3, 20162.3Least Developed Countries. EARNED ROYALTY shall not be due and payable to JHU on NET REVENUES generated from: (i)LICENSED PRODUCTS sold in Least Developed Countries as defined by the United Nations Country Classification in the mostrecent United Nations’ publication “Statistical Annex” (“LEAST DEVELOPED COUNTRIES”); or (ii) LICENSED PRODUCTS soldto the Public Sector providing LICENSED PRODUCTS at a Cost-Based Price in such Least Developed Countries, but only ifCOMPANY sells such LICENSED PRODUCTS at COMPANY’s cost of production thereof.3. MINIMUM ANNUAL ROYALTIES3.1The minimum annual royalties pursuant to the Agreement are:1st anniversary of the EFFECTIVE DATE and each subsequent anniversary of the EFFECTIVE DATE during the term:Three-thousand dollars (3000)3.2Earned Royalties payable for each calendar year are creditable on a non-cumulative basis against MINIMUM ANNUALROYALTIES for that year only.4. LIQUIDITY EVENT4.1COMPANY will pay JHU a fee equal one percent (1%) of the Aggregate Consideration received by the COMPANY, or the totalamount received by stockholders of COMPANY, upon the occurrence of a Liquidity Event. Such fee shall be paid after only thefirst to occur of either a Liquidation Event or an Initial Public Offering. The respective fees, when and if payable, shall be paidupon closing; except that if there are additional contingent amounts (“Trailing Consideration”) payable upon the occurrence ofsubsequent events, then the Trailing Consideration shall be due and payable to JHU within thirty (30) days after receipt thereofby COMPANY.4.2For a Liquidity Event, the fee required under Section 4.1 of this Exhibit A above shall be payable to JHU by COMPANY in thesame form as the proceeds paid or payable to either COMPANY or its security holders, whether in cash, securities or otherproperty, and in the same proportion as such form of consideration is paid or payable to COMPANY or its security holders.Notwithstanding the foregoing, in the event the form of consideration paid or payable includes securities for which there is notan active public market, in lieu of paying that portion of the fee with such securities COMPANY will make a cash payment to JHUequal to the fair market value of such securities. The valuation of such securities shall be determined in accordance with thedefinition of “Aggregate Consideration” set forth below.4.3For an Initial Public Offering, the fee shall be payable in the form of cash, and shall be based upon the Pre Money Valuation.Source: VIRTUOSO SURGICAL, INC., 1-A, 12/27/201913May 3, 20164.4“Aggregate Consideration” means the amount equal to:4.4.1In the case of an Asset Sale, the sum of: (a) all cash, and the fair market value of all securities or other propertytransferred to COMPANY at the time of the transaction, less all current and long-term liabilities (but not contingentliabilities) of COMPANY that are not discharged or assumed by the buyer (or its affiliates) in connection with the AssetSale; and (b) all cash, and the fair market value of all securities and other property for Trailing Consideration payable toCOMPANY, when and if actually paid; or4.4.2In the case of a Merger or Stock Sale, the sum of: (a) all cash, and the fair market value of all securities and otherproperty transferred to the stockholders of COMPANY (and any option holders or warrant holders) in return for theirstock (or options or warrants) in COMPANY at the time of the transaction, and (b) all cash, and the fair market value ofall securities and other property transferred to the stockholders of COMPANY (and any option holders or warrantholders) for Trailing Consideration payable to the holders of COMPANY’s securities, when and if actually paid.4.4.3The valuation of any securities or other property shall be determined by reference to the operative transactionagreement for a respective Merger, Stock Sale or Asset Sale, provided that, if no such valuation is readily determinablefrom such operative transaction agreement, then for securities for which there is an active public market:(a)If traded on a securities exchange or the NASDAQ Stock Market, the value shall be deemed to be the averageof the closing prices of the securities on such exchange or market over the thirty day (30) period ending three(3) days prior to the closing of such transaction; or(b)If actively traded over-the-counter, the value shall be deemed to be the average of the closing bid prices overthe thirty day (30) period ending three (3) days prior to the closing of such transaction.(c)The method of valuation of securities subject to investment letters or other similar restrictions on freemarketability shall take into account an appropriate discount from the market value as determined pursuant toclause (a) or (b) above so as to reflect the approximate fair market value thereof.(d)For securities for which there is no active public market, the value shall be the fair market value thereof aseither: (i) determined in good faith by the Board of Directors of COMPANY; (ii) approved by JHU, suchapproval not to be unreasonably withheld; or (iii) determined by a third party appraiser appointed and paid forby COMPANY.Source: VIRTUOSO SURGICAL, INC., 1-A, 12/27/201914May 3, 20164.5“Pre-Money Valuation” means the amount equal to the product of: (i) the price per share of common stock sold in the InitialPublic Offering, and (ii) the total number of outstanding shares of common stock of COMPANY immediately prior to the closingof the Initial Public Offering, determined on a fully diluted, as converted into common stock basis, giving effect to any stock split,stock dividend, stock combination, recapitalization or similar action impacting COMPANY’s capitalization that occurs, or isdeemed to occur, upon consummation of the Initial Public Offering.Source: VIRTUOSO SURGICAL, INC., 1-A, 12/27/201915May 3, 2016EXHIBIT BQUARTERLY SALES ROYALTY REPORTFOR NON-EXCLUSIVE LICENSE AGREEMENT A29889BETWEENVIRTUOSO SURGICAL, INC. AND THE JOHNS HOPKINS UNIVERSITYEFFECTIVE DATE OF AGREEMENT _________________FOR PERIOD OF _________ TO _________TOTAL ROYALTIES DUE FOR THIS PERIOD_________PRODUCTID NO.PRODUCTNAMEJHUREFNO.PTCOMMERCIALSALE DATETOTAL NESALES/SERVICESROYALTYRATEAMOUNTDUE Please provide the JHU Ref. C04873This report format is to be used to report quarterly royalty statements to JHU. It should be placed on Company letterhead and accompanyany royalty payments due for the reporting period. This report shall be submitted even if no sales are reported.Source: VIRTUOSO SURGICAL, INC., 1-A, 12/27/201916May 3, 2016EXHIBIT CJHU RefNumberTechnology TitleInventorsCountry/C04873Active Cannulas for Bio-sensing and SurgicalInterventionAllison M. OkamuraNoah J. CowanRobert James Webster, IIIRussell H. TaylorJapan2008-541319C04873Active Cannulas for Bio-sensing and SurgicalInterventionAllison M. OkamuraNoah J. CowanRobert James Webster, IIIRussell H. TaylorEuropean Patent Office06844376.1C04873Active Cannulas for Bio-sensing and SurgicalInterventionAllison M. OkamuraNoah J. CowanRobert James Webster, III Russell H. TaylorCanada2,630,061C04873Active Cannulas for Bio-sensing and SurgicalInterventionAllison M. OkamuraNoah J. CowanRobert James Webster, IIIRussell H. TaylorJapan2012-1390885550682C04873Active Cannulas for Bio-sensing and SurgicalInterventionAllison M. OkamuraNoah J. CowanRobert James Webster, IIIRussell H. TaylorJapan 2015-094824C04873Active Cannulas for Bio-sensing and SurgicalInterventionAllison M. OkamuraNoah J. CowanRobert James Webster, IIIRussell H. TaylorJapan 2014-000372C04873Active Cannulas for Bio-sensing and SurgicalInterventionAllison M. OkamuraNoah J. CowanRobert James Webster, IIIRussell H. TaylorChina200680050046.8ZL 200680050046.8C04873Active Cannulas for Bio-sensing and SurgicalInterventionAllison M. OkamuraNoah J. CowanRobert James Webster, IIIRussell H. TaylorUnited States 8,152,756C04873Active Cannulas for Bio-sensing and SurgicalInterventionAllison M. OkamuraNoah J. CowanRobert James Webster, IIIRussell H. TaylorUnited States 8,715,226Source: VIRTUOSO SURGICAL, INC., 1-A, 12/27/2019